Today: 11 June 2026
Salesforce stock price steadies near $214 after software rout; traders brace for AI tests next week
30 January 2026
1 min read

Salesforce stock price steadies near $214 after software rout; traders brace for AI tests next week

New York, Jan 30, 2026, 11:16 ET — Regular session

  • Salesforce (CRM) held steady in early trading following Thursday’s sharp selloff in software stocks.
  • Disappointing reports from SAP and ServiceNow stoked concerns that AI might dampen demand for subscription software.
  • The Feb. 6 U.S. jobs report and next week’s megacap earnings will be key tests for risk appetite.

Salesforce shares barely moved on Friday, hovering near $214.09 after an opening price of $215.06. Early trading saw the stock fluctuate between $211.66 and $215.44.

This shift is significant since software stocks are behaving like a referendum on AI—not just if it boosts sales, but if it displaces parts of current customer spending. Salesforce finds itself caught in the middle, as investors wrestle with how quickly “AI agents” evolve from demos to revenue-generating products.

This comes amid a wave of earnings reports hitting U.S. markets, where a handful of disappointing numbers can quickly trigger widespread de-risking. Subscription software stocks usually take the first hit when sentiment shifts.

Thursday’s sell-off gained momentum after SAP issued a cautious cloud forecast and ServiceNow’s shares dropped post-earnings, fueling concerns that AI tools might disrupt the subscription-based SaaS model. SAP plunged over 16%, ServiceNow dropped 11%, Salesforce slid 7.1%, and the S&P 500 Software and Services Index fell 8.7%, hitting its lowest level in nine months. “The market is pricing a worst-case scenario that software is dead,” said Adam Turnquist, chief technical strategist at LPL Financial. Reuters

Microsoft slumped 10%, weighed down by cloud results that didn’t reassure investors jittery over heavy AI spending. “There are some genuine concerns that AI investments will eat the software companies’ lunches,” said John Praveen, managing director and co-CIO at Paleo Leon. Reuters

ServiceNow, a key player in the enterprise software sector, projects fiscal 2026 subscription revenue between $15.53 billion and $15.57 billion. The board also greenlit an additional $5 billion in buybacks, including a $2 billion accelerated repurchase. Valoir CEO Rebecca Wettemann noted the company is growing both “organically and by acquisition” as it ramps up AI partnerships. Reuters

But after such a sharp decline, there’s not much margin left for another letdown. If clients start delaying renewals, cutting back on seats, or pushing harder on prices as AI tools become cheaper and more accessible, the sell-off in Salesforce and other software stocks might stretch beyond a single day of panic.

Another risk is headline-chasing, where traders fixate on the latest cloud numbers rather than the underlying, longer sales cycle. This can drive sharp swings, even if the fundamentals barely change.

Next week will deliver earnings from Alphabet and Amazon, alongside the Feb. 6 U.S. jobs report—a mix that might shift rate forecasts and investor appetite for pricey software stocks. “The onus is going to be on them to deliver,” said Jim Baird, chief investment officer at Plante Moran Financial Advisors. Reuters

Stock Market Today

  • Urban Edge Properties (UE) Valuation Update Amid Share Price Gains
    June 11, 2026, 10:53 AM EDT. Urban Edge Properties (UE), a New York-based retail-focused REIT, saw its share price rise to $23.76, reflecting a 9.14% gain over one month and 24.40% year-to-date. The stock's 1-year total shareholder return stands at 31.99%, with a 3-year return of 76.37%, showing strong momentum. Despite trading near its $23.43 analyst price target, UE shows a 5.23% discount to an intrinsic value estimate of $25.07 based on discounted cash flow (DCF) analysis. The debate centers on whether UE is slightly overvalued or undervalued given redevelopment projects boosting net operating income (NOI) and potential risks from tenant pressure and geographic concentration in the Northeast. Investors must weigh valuation models and growth prospects carefully before acting.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Silver price today: XAG/USD tumbles near $100 as Warsh Fed pick jolts metals
Previous Story

Silver price today: XAG/USD tumbles near $100 as Warsh Fed pick jolts metals

Netflix stock steadies near $83 as Bernstein sticks with $115 target and Warner deal faces new pushback
Next Story

Netflix stock steadies near $83 as Bernstein sticks with $115 target and Warner deal faces new pushback

Go toTop